# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.43) ...
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.
Oppenheimer analyst Leland Gershell initiates coverage on Immunovant (NASDAQ:IMVT) with a Outperform rating and announces Pr...
Truist Securities analyst Robyn Karnauskas reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $48 price target.
Goldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price T...